{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01851070",
      "OrgStudyIdInfo": {
        "OrgStudyId": "MSB-RA001"
      },
      "Organization": {
        "OrgFullName": "Mesoblast, Ltd.",
        "OrgClass": "INDUSTRY"
      },
      "BriefTitle": "A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor",
      "OfficialTitle": "A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor"
    },
    "StatusModule": {
      "StatusVerifiedDate": "June 2020",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "July 2013",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "May 2016",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "March 2017",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "April 19, 2013",
      "StudyFirstSubmitQCDate": "May 9, 2013",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "May 10, 2013",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "June 25, 2020",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "June 26, 2020",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Sponsor"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Mesoblast, Ltd.",
        "LeadSponsorClass": "INDUSTRY"
      },
      "CollaboratorList": {
        "Collaborator": [
          {
            "CollaboratorName": "PPD",
            "CollaboratorClass": "INDUSTRY"
          }
        ]
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and who have had an incomplete response to at least one TNF-alpha inhibitor."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Rheumatoid Arthritis"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "Randomized",
        "DesignInterventionModel": "Parallel Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "Triple",
          "DesignWhoMaskedList": {
            "DesignWhoMasked": [
              "Participant",
              "Investigator",
              "Outcomes Assessor"
            ]
          }
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "48",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Normal Saline Placebo",
            "ArmGroupType": "Placebo Comparator",
            "ArmGroupDescription": "Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Allogeneic Mesenchymal Precursor Cells"
              ]
            }
          },
          {
            "ArmGroupLabel": "Allogeneic Mesenchymal Precursor Cells",
            "ArmGroupType": "Active Comparator",
            "ArmGroupDescription": "Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Drug: Normal Saline"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Drug",
            "InterventionName": "Allogeneic Mesenchymal Precursor Cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Normal Saline Placebo"
              ]
            }
          },
          {
            "InterventionType": "Drug",
            "InterventionName": "Normal Saline",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Allogeneic Mesenchymal Precursor Cells"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion",
            "PrimaryOutcomeDescription": "To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 4 months and who have had an incomplete response to at least one course of a TNFα inhibitor.\n\nOverall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs and Chest x-ray.",
            "PrimaryOutcomeTimeFrame": "12 weeks post IV Infusion"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA",
            "SecondaryOutcomeDescription": "To assess the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to least one TNFα inhibitor.",
            "SecondaryOutcomeTimeFrame": "12 weeks post IV infusion with MPCs"
          },
          {
            "SecondaryOutcomeMeasure": "Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA",
            "SecondaryOutcomeDescription": "To evaluate the long-term efficacy and safety of allogeneic MPCs over the entire study duration in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to at least one TNFα inhibitor\n\nSafety will be assessed according to the following:\n\nAdverse events/serious adverse events (\"primary endpoint\")\nVital signs\nPhysical examination\nClinical laboratory tests\nElectrocardiogram\nChest x-ray (CXR)\n\nEfficacy will be assessed according to the following:\n\nACR20/50/70\nDAS28 (mean changes from baseline as measured by using hsCRP and ESR)\nMean changes from baseline in all components of the ACR core response criteria\nRemissions (as defined in the 2011 Joint Statement of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)\nJoint erosion of hands and wrists assessed via x-ray\n\nPatient-reported outcomes\n\nSF36v2\nHAQ_DI",
            "SecondaryOutcomeTimeFrame": "52 weeks post IV Infusion"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nMales and Females ages 18-80 years old\nActive rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification criteria for the diagnosis of RA.\nMust be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-CCP3) but without extra-articular disease or functional limitation\n\nPatient with active RA defined as:\n\n≥ 4 tender joint count (TJC) 28 joint count at screening and\n≥ 4 swollen joint count (SJC) count 28 joint count at screening\nESR ≥ 28 mm/hr or hsCRP >2.0 mg/L\nPatient has been taking MTX for at least 4 months with dose and route of administration stable for at least 8 weeks prior to screening\nPatient has had an inadequate response to at least one TNFα inhibitor with last dose at least 6 weeks prior to screening\nUse of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is permitted but must be stable for at least 3 months prior to screening\n\nExclusion Criteria:\n\nPregnant women or women who are breastfeeding.\nOther investigational therapy received within 8 weeks or five half-lives (whichever is longer) prior to Screening (except as in exclusion #13).\nKnown or suspected alcohol or drug abuse within three years preceding Screening.\nAutoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis)\nHistory of or current inflammatory joint disease other than RA (such as tophaceous gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis are excluded.\nBedridden or confined to a wheelchair or patients with > 3 arthroplasties due to RA.\nHistory of diagnosed and/or treated malignancy with no evidence of recurrence in past 5 years\nSurgical procedures planned to occur during the trial (these patients may be rescreened following completion of and recovery from the surgical procedure).\nUse of TNFα inhibitor for treatment of RA at time of screening or within the 6 weeks prior to screening.\nPrior use of biologic agent for treatment of RA within 6 weeks prior to screening",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "80 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Donna Skerrett, MD, MS",
            "OverallOfficialAffiliation": "Mesoblast, Ltd.",
            "OverallOfficialRole": "Study Director"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Pinnacle Research Group",
            "LocationCity": "Anniston",
            "LocationState": "Alabama",
            "LocationZip": "36207",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Arthrocare Arthritis Care and Research PC",
            "LocationCity": "Gilbert",
            "LocationState": "Arizona",
            "LocationZip": "85234",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Triwest Research Associates",
            "LocationCity": "El Cajon",
            "LocationState": "California",
            "LocationZip": "92020",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "UCLA",
            "LocationCity": "Los Angeles",
            "LocationState": "California",
            "LocationZip": "90025",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Inland Rheumatology Clinical Trials Incorporated",
            "LocationCity": "Upland",
            "LocationState": "California",
            "LocationZip": "91786",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Ocala Rheumatology Research Center",
            "LocationCity": "Ocala",
            "LocationState": "Florida",
            "LocationZip": "34474",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Arthritis Center",
            "LocationCity": "Palm Harbor",
            "LocationState": "Florida",
            "LocationZip": "34684",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Sarasota Arthritis Research Center",
            "LocationCity": "Sarasota",
            "LocationState": "Florida",
            "LocationZip": "34239",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "McIlwain Medical Group",
            "LocationCity": "Tampa",
            "LocationState": "Florida",
            "LocationZip": "33614",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "JHU Arthritis Center Baltimore",
            "LocationCity": "Baltimore",
            "LocationState": "Maryland",
            "LocationZip": "21224",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Arthritis Treatment Center",
            "LocationCity": "Frederick",
            "LocationState": "Maryland",
            "LocationZip": "21702",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Reliant Medical Group",
            "LocationCity": "Worcester",
            "LocationState": "Massachusetts",
            "LocationZip": "01605",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Mayo Clinic",
            "LocationCity": "Rochester",
            "LocationState": "Minnesota",
            "LocationZip": "55905",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Office of Ramesh C. Gupta, MD",
            "LocationCity": "Fair Lawn",
            "LocationState": "New Jersey",
            "LocationZip": "07410",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "DJL Clinical Research",
            "LocationCity": "Charlotte",
            "LocationState": "North Carolina",
            "LocationZip": "28210",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Health Research of Oklahoma",
            "LocationCity": "Oklahoma City",
            "LocationState": "Oklahoma",
            "LocationZip": "73102",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "University of Pittsburgh",
            "LocationCity": "Pittsburgh",
            "LocationState": "Pennsylvania",
            "LocationZip": "15261",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "West Tennessee Research Institute",
            "LocationCity": "Jackson",
            "LocationState": "Tennessee",
            "LocationZip": "38305",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Accurate Clinical Research",
            "LocationCity": "Houston",
            "LocationState": "Texas",
            "LocationZip": "77034",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Texas Arthritis Research Center",
            "LocationCity": "San Antonio",
            "LocationState": "Texas",
            "LocationZip": "78217",
            "LocationCountry": "United States"
          },
          {
            "LocationFacility": "Royal Prince Alfred Hospital",
            "LocationCity": "Camperdown",
            "LocationState": "New South Wales",
            "LocationZip": "2050",
            "LocationCountry": "Australia"
          },
          {
            "LocationFacility": "Southern Clinical Research Pty Ltd",
            "LocationCity": "Hobart",
            "LocationState": "Tasmania",
            "LocationZip": "7000",
            "LocationCountry": "Australia"
          },
          {
            "LocationFacility": "Emeritus Research",
            "LocationCity": "Malvern",
            "LocationState": "Victoria",
            "LocationZip": "3145",
            "LocationCountry": "Australia"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001168",
            "ConditionMeshTerm": "Arthritis"
          },
          {
            "ConditionMeshId": "D000001172",
            "ConditionMeshTerm": "Arthritis, Rheumatoid"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000007592",
            "ConditionAncestorTerm": "Joint Diseases"
          },
          {
            "ConditionAncestorId": "D000009140",
            "ConditionAncestorTerm": "Musculoskeletal Diseases"
          },
          {
            "ConditionAncestorId": "D000012216",
            "ConditionAncestorTerm": "Rheumatic Diseases"
          },
          {
            "ConditionAncestorId": "D000003240",
            "ConditionAncestorTerm": "Connective Tissue Diseases"
          },
          {
            "ConditionAncestorId": "D000001327",
            "ConditionAncestorTerm": "Autoimmune Diseases"
          },
          {
            "ConditionAncestorId": "D000007154",
            "ConditionAncestorTerm": "Immune System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3628",
            "ConditionBrowseLeafName": "Arthritis",
            "ConditionBrowseLeafAsFound": "Arthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M3632",
            "ConditionBrowseLeafName": "Arthritis, Rheumatoid",
            "ConditionBrowseLeafAsFound": "Rheumatoid Arthritis",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M9773",
            "ConditionBrowseLeafName": "Joint Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11249",
            "ConditionBrowseLeafName": "Musculoskeletal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M14197",
            "ConditionBrowseLeafName": "Rheumatic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5475",
            "ConditionBrowseLeafName": "Collagen Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M5616",
            "ConditionBrowseLeafName": "Connective Tissue Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M3781",
            "ConditionBrowseLeafName": "Autoimmune Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M9352",
            "ConditionBrowseLeafName": "Immune System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC05",
            "ConditionBrowseBranchName": "Musculoskeletal Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC17",
            "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC20",
            "ConditionBrowseBranchName": "Immune System Diseases"
          }
        ]
      }
    }
  }
}